Evidence map›Paper›PMID 40093597›Full record

ArticleDigital biomarkers

Analysis Method of Real-World Digital Biomarkers for Clinical Impact in Cancer Patients.

Ingrid Oakley-Girvan, Yaya Zhai, Reem Yunis, Raymond Liu, Sharon W Davis, Ai Kubo, Sara Aghaee, Jennifer M Blankenship, Kate Lyden, Elad Neeman

Abstract read
In one paragraph

Article in Digital biomarkers. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ingrid Oakley-GirvanMedable Inc., Strategy and Science Departments, Palo Alto, CA, USA.
Yaya ZhaiVivosense, Inc., Newport Coast, CA, USA.
Reem YunisMedable Inc., Strategy and Science Departments, Palo Alto, CA, USA.
Raymond LiuKaiser Permanente Northern California, Division of Research, Oakland, CA, USA.
Sharon W DavisMedable Inc., Strategy and Science Departments, Palo Alto, CA, USA.
Ai KuboKaiser Permanente Northern California, Division of Research, Oakland, CA, USA.
Sara AghaeeKaiser Permanente Northern California, Division of Research, Oakland, CA, USA.
Jennifer M BlankenshipVivosense, Inc., Newport Coast, CA, USA.
Kate LydenVivosense, Inc., Newport Coast, CA, USA.
Elad NeemanKaiser Permanente Northern California, San Rafael Medical Center, San Rafael, CA, USA.

Funding

NCI NIH HHS HHSN261201800010CNCI NIH HHS HHSN261201800010I
6 · The paper itself

Abstract

Introduction: Wearable technologies can enhance measurements completed from home by participants in decentralized clinical trials. These measurements have shown promise in monitoring patient wellness outside the clinical setting. However, there are challenges in handling data and its interpretation when using consumer wearables, requiring input from statisticians and data scientists. This article describes three methods to estimate daily steps to address gaps in data from the Apple Watch in cancer patients and uses one of these methods in an analysis of the association between daily step count estimates and clinical events for these patients. Methods: A cohort of 50 cancer patients used the DigiBioMarC app integrated with an Apple Watch for 28 days. We identified different gap types in watch data based on their length and context to estimate daily steps. Cox proportional hazards regression models were used to determine the association between step count and time to death or time to first clinical event. Decision tree modeling and participant clustering were also employed to identify digital biomarkers of physical activity that were predictive of clinical event occurrence and hazard ratio to clinical events, respectively. Results: Among the three methods explored to address missing steps, the method that identified different step data gap types according to their duration and context yielded the most reasonable estimate of daily steps. Ten hours of waking time was used to differentiate between sufficient and insufficient measurement days. Daily step count on sufficient days was the most promising predictor of time to first clinical event ( Conclusion: We have developed an effective way to estimate daily steps of consumer wearable data containing unknown data gaps. Daily step counts on days with sufficient sampling are a strong predictor of the timing and occurrence of clinical events, with individuals exhibiting higher daily step counts having reduced hazard of death or clinical events.

Indexed as

Adverse clinical eventsBring your own deviceCancerDaily step countDigital healthPhysical activitySufficient step countWearables

Identifiers

PMID40093597
PMCPMC11908807

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.